Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (91)	8/9/2001 4:55:46 PM
From: sim1	Respond to of 222

Corixa receives multiple U.S. patents in oncology programs 08/09/2001 Seattle, August 9, 2001 – Corixa Corporation (Nasdaq: CRXA), a developer of immunotherapeutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company three patents, including a method potentially useful in establishing the optimal radiation dose given to a patient based on the patient’s specific traits – a method used in administering Bexxar™ (tositumomab, iodine I 131 tositumomab). Corixa is seeking marketing approval of Bexxar for the treatment of relapsed or refractory, low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. The first patent awarded to Corixa -- U.S. Patent 6,251,362 -- relates to the administration of radiopharmaceutical compounds for the therapy of cancer and other diseases. Radiopharmaceuticals are compounds composed of radioactive isotopes often bound to other molecules. When radioactive labels are attached to monoclonal antibodies that are specific for a particular diseased tissue, the antibodies can selectively direct radiation to the specific disease site. However, if a patient is given too much of a given radioactive isotope-antibody conjugate, normal tissue can be adversely affected, creating unwarranted and dangerous toxicities. U.S. patent 6,251,362 covers the administration and dosing of radiopharmaceuticals to minimize toxicity while keeping the dosage high enough to successfully treat the disease. The patent covers a variety of methods of determining radioisotope levels in patients after therapeutic administration, including, but not limited to, imaging. Additional patents issued today include U.S. Patents 6,262,245 and 6,261,562 covering DNA sequences and methods of use for multiple prostate antigens potentially useful as vaccine or antibody targets. “The granting of these patents provides us with strong protection of our technology and intellectual property in the United States,” said Steven Gillis, Ph.D., chairman and chief executive officer at Corixa. “Specifically, the radiopharmaceutical compound patent further protects Corixa’s approach of accurate and optimized dosing when administering a radioimmunotherapy like Bexxar. We are pleased that the U.S. Patent Office has granted us protection for these additional methods in the dosing process. We are pleased with these successes as we continue to pursue comprehensive protection of Corixa’s intellectual property.”...